Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 27, 2020 02:00 ET | Source: Novartis International AG

Novartis au T3: performance solide, croissance de 11% du résultat opérationnel core, chiffre d’affaires net proche de l’an dernier, pipeline en fort progrès; hausse du résultat opérationnel core prévu

Chiffre d’affaires net des activités poursuivies1 au T3 en ligne avec celui de l’exercice précédent (tcc2, +1% USD): Les moteurs de la croissance ont été notamment Entresto USD 632 millions (+45%...
October 27, 2020 02:00 ET | Source: Novartis International AG

Novartis im 3. Qu. mit solider Performance: operatives Kernergebnis steigt um 11%, Nettoumsatz auf Vorjahresniveau, starke Pipeline-Fortschritte; Jahresprognose für operatives Kernergebnis angehoben

Im dritten Quartal 2020 lag der Nettoumsatz der fortzuführenden Geschäftsbereiche1 auf dem Niveau des Vorjahres (kWk2, +1% USD): Zu den Wachstumsträgern gehörten Entresto (USD 632 Millionen,...
October 27, 2020 02:00 ET | Source: Novartis International AG

Novartis delivers solid Q3 performance with 11% core operating income growth, net sales in line with prior year, strong pipeline progression. Upgrades full year core operating income guidance.

Q3 net sales from continuing operations1 were in line with prior year (cc2, +1% USD): Growth drivers included Entresto USD 632 million (+45% cc), Zolgensma USD 291 million (+79% cc), Cosentyx USD 1...
October 26, 2020 02:15 ET | Source: Novartis International AG

Novartis presents promising interim Phase II data of potential first-in-class oral therapy iptacopan (LNP023) in rare renal disease C3 glomerulopathy (C3G)

C3 glomerulopathy (C3G) is a rare renal disease, affecting young patients with a poor prognosis and significant unmet need.1–3 Iptacopan (LNP023) is a potential first-in-class, oral, potent and...
October 16, 2020 07:30 ET | Source: Novartis International AG

Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol

If approved, inclisiran will be the first and only small interfering RNA (siRNA) in Europe for patients with hypercholesterolemia or mixed dyslipidemia1Cardiovascular disease (CVD) claims 3.9...
October 01, 2020 01:15 ET | Source: Novartis International AG

Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonged event-free survival, increased motor function and milestone achievement

Nearly two-thirds of patients (65.6%) in STR1VE-EU have already achieved developmental motor milestones not observed in the natural history of SMA Type 1 at a mean duration of follow-up of 10.6...
September 23, 2020 01:15 ET | Source: Novartis International AG

Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program

Novartis Gene Therapies to initiate new pivotal confirmatory study to evaluate use of AVXS-101 intrathecal (IT) formulation in older patients with SMA to further support registration Basel, September...
September 19, 2020 10:25 ET | Source: Novartis International AG

Novartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation

In SOLAR-1 final analysis, Piqray (alpelisib) plus fulvestrant demonstrated 8 months clinically relevant improvement in overall survival (OS) in HR+/HER2- advanced breast cancer (aBC) patients with a...
September 19, 2020 10:20 ET | Source: Novartis International AG

Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma

Based on unprecedented progression-free survival results, Tafinlar (dabrafenib) + Mekinist (trametinib) confirmed as standard-of-care, targeted therapy for advanced BRAF-mutated melanoma1-4 Data show...
September 16, 2020 17:02 ET | Source: Novartis International AG

Novartis Tafinlar® + Mekinist® demonstrates long-term, relapse-free survival benefit for high-risk, stage III melanoma patients in study published in NEJM

COMBI-AD is first trial to demonstrate 5-year relapse-free survival with targeted therapy as adjuvant treatment in high-risk patients with stage III BRAF-mutated melanoma1 Adjuvant treatment...